
Xenon Pharmaceuticals Inc.
NASDAQ:XENE
35.18 (USD) • At close March 13, 2025
Overzicht | Financiële gegevens
Bedrijfsnaam | Xenon Pharmaceuticals Inc. |
Symbool | XENE |
Munteenheid | USD |
Prijs | 35.18 |
Beurswaarde | 2,692,775,704 |
Dividendpercentage | 0% |
52-weken bereik | 33.27 - 46 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Mr. Ian C. Mortimer C.M.A., CPA, CMA, CPA, M.B.A., MBA |
Website | https://www.xenon-pharma.com |
An error occurred while fetching data.
Over Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopathy; and XEN1101, A Kv7 potassium
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)